← Back to news
S

Seeking Alpha: News

Pacific Biosciences to collaborate with foundations on rare genetic disease therapies

S

BHP not planning rival bid as Rio Tinto pursues Glencore mega-merger - Reuters

S

BARK rallies 31% after attracting a go-private offer

S

Ultragenyx sees FY25 revenue between $672M and $674M

S

Axogen sees Q4 net sales of up to $59.9M and FY2025 at $225.2M

S

Dynavax gains on disclosure another bidder interested after deal announced

S

PTC Therapeutics projects FY26 product revenue between $700M to $800M

S

Boot Barn issues positive guidance update on strong western boots, denim demand

S

CACI International secures $416 million contract from U.S. Navy

S

Akebia therapeutics announces corporate updates and 2026 pipeline outlook

S

HUB Cyber Security appoints Limor Zur-Stoller as CFO

S

AmpliTech receives $9M from $4 unit subscription rights offering

S

UBS opposes Swiss proposal to tighten banking rules after Credit Suisse collapse - report

S

Lulu’s Fashion Lounge surges 45% after Friedland Enterprises takes 5% stake, pushes governance reforms

S

Petco seeks to refinance $1.5B debt, reaffirms guidance

S

The best large cap energy stocks by EPS revisions

S

Datadog, Appian both receive upgrades to Overweight by Morgan Stanley

S

HealthEquity expects FY 2027 revenue between $1.38B and $1.41B; shares down over 7%

S

Apple chooses Google's Gemini to run next version of Siri

S

Maersk weighs using more ethanol use for its ships to cut reliance on China - FT

S

Descartes gets an upgrade, while Snowflake, DoubleVerify and GitLab cut at Barclays

S

Financial stocks with weakest earnings momentum heading into reporting season

S

Canadian National Railway plays defense against the Union Pacific-Norfolk Southern merger plan

S

FEI-Zyfer secures contracts totaling about $6M

S

Crypto startup BitGo files to raise up to $201M in IPO

S

Financial stocks with strongest earnings momentum heading into reporting season

S

Stoke down as FDA rebuffs expedited review of zorevunersen for Dravet syndrome

S

MDxHealth sees Q4 net sales of up to $30.5M and FY25 net sales of $109M

S

Amkor Technology downgraded at UBS on more balanced risk-reward

S

China quotas deepen Brazil’s beef production slowdown

S

Wall Street pushes higher despite Powell investigation

S

Beam Therapeutics shares jump on progress in precision genetic medicines and 2026 strategic plans

S

Meta appoints Dina Powell McCormick for new role, receives Trump praise

S

GitLab, Nutanix receive downgrades to Equal-weight by Morgan Stanley

S

Allurion expects FY25 net sales of 15M

S

Paramount files lawsuit against Warner Bros; intends to nominate director slate (update)

S

Groupe Dynamite projects FY2025 comparable store sales growth guidance between 26.5% - 27%

S

CVRx reports preliminary 2025 results, issues 2026 guidance

S

Planet Labs secures 9-figure satellite deal from Sweden

S

Venture Global cuts FY 2025 profit guidance on volatile LNG prices

S

Why the bond market is not signaling a need for lower rates – Yardeni Research

S

Veracyte reports Q4 preliminary revenue in the range of $138M - $140M

S

Alignment Healthcare guides 2026 membership growth up to 27%

S

Sekur Private Data launches $1.05M non-brokered private placement

S

Silver spikes as safe-haven demand jumps on Powell investigation

S

Pacific Biosciences of California reports prelim Q4, FY revenue above estimate

S

Omada Health expects Q4 revenue to be between $72M and $74M

S

Inogen sees Q4 net sales of $82M and $349M for the full-year 2025

S

Trump to interview Rick Rieder for Fed chair this week - report

S

Vanguard FTSE Canadian High Dividend Yield Index ETF declares CAD 0.1705 dividend

S